Belumosudil Combination Therapy with Extracorporeal Photopheresis in Chronic Graft Versus Host Disease: Results from the Rockstar Study

Key Points

• Improved outcomes are observed in chronic graft versus host disease with combination therapy.
• Significant positive response rates indicate benefits when using belumosudil alongside extracorporeal photopheresis.
• Observational analysis assesses the impact of belumosudil and photopheresis on immune response variations.
• This combination therapy may enhance treatment options for patients suffering from chronic graft versus host disease.